Molecular Determinants of Sotorasib Efficacy in Patients with Advanced KRASG12C-mutated NSCLC By Ogkologos - June 6, 2025 837 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from integrated analyses of sotorasib clinical efficacy biomarkers in the CodeBreaK 100 and CodeBreaK 200 studies Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR News digest – targeted ‘lava lamp’ treatment, skin cancer biopsies and... June 20, 2020 How longer waiting times are impacting teens and young adults April 27, 2023 How I Found a Meaningful Career After Cancer October 26, 2020 News digest – sponge on a string, junk food watershed, prostate... August 1, 2020 Load more HOT NEWS Reflections from our chief clinician: The essential role of our research... Trastuzumab Deruxtecan Prolongs PFS After Endocrine-Based Therapy in Patients with HR-positive,... Oncotype DX Breast Cancer Test May Be Less Accurate for Black... Rookie Cop Saves Infant From Choking
